scholarly journals Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

Haemophilia ◽  
2021 ◽  
Author(s):  
Mark T. Reding ◽  
Ingrid Pabinger ◽  
Pal Andre Holme ◽  
Lone Poulsen ◽  
Claude Negrier ◽  
...  
Keyword(s):  
Prophylactic Treatment ◽  
Extension Study ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Safety And Efficacy

scholarly journals PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A

Haemophilia ◽  
2021 ◽  
Author(s):  
Maria Elisa Mancuso ◽  
Tina Biss ◽  
Kathelijn Fischer ◽  
Monika Maas Enriquez ◽  
MacGregor Steele ◽  
...  
Keyword(s):  
Extension Study ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Safety And Efficacy

scholarly journals Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial

Haemophilia ◽  
2018 ◽  
Vol 24 (6) ◽  
pp. e391-e394 ◽  
Author(s):  
Steven R. Lentz ◽  
Dragana Janic ◽  
Kaan Kavakli ◽  
Predrag Miljic ◽  
Johannes Oldenburg ◽  
...  
Keyword(s):  
Haemophilia A ◽  
Severe Haemophilia ◽  
Safety And Efficacy ◽  
Bleeding Episodes ◽  
The Guardian ◽  
Extension Trial

scholarly journals Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Haemophilia ◽  
2015 ◽  
Vol 22 (1) ◽  
pp. 72-80 ◽  
Author(s):  
B. Nolan ◽  
J. Mahlangu ◽  
D. Perry ◽  
G. Young ◽  
R. Liesner ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Factor Viii ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Safety And Efficacy ◽  
Fc Fusion Protein
Sign in / Sign up

Export Citation Format

Share Document